[English] 日本語
Yorodumi- EMDB-71718: Locally-refined structure of alpha2a adrenergic receptor in compl... -
+
Open data
-
Basic information
| Entry | ![]() | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Title | Locally-refined structure of alpha2a adrenergic receptor in complex with Go heterotrimer, scFv16, and N-(5-methylnaphthalen-1-yl)pyridin-4-amine (compound 4905) | |||||||||
Map data | Local refinement sharpened map of Alpha2a adrenergic receptor in complex with compound 4905 | |||||||||
Sample |
| |||||||||
Keywords | Receptor / Drug / Complex / GPCR / G-protein / scFv16 / MEMBRANE PROTEIN | |||||||||
| Function / homology | Function and homology informationnegative regulation of uterine smooth muscle contraction / alpha2-adrenergic receptor activity / Adrenaline signalling through Alpha-2 adrenergic receptor / alpha-2C adrenergic receptor binding / epinephrine binding / phospholipase C-activating adrenergic receptor signaling pathway / alpha-1B adrenergic receptor binding / negative regulation of norepinephrine secretion / negative regulation of insulin secretion involved in cellular response to glucose stimulus / negative regulation of epinephrine secretion ...negative regulation of uterine smooth muscle contraction / alpha2-adrenergic receptor activity / Adrenaline signalling through Alpha-2 adrenergic receptor / alpha-2C adrenergic receptor binding / epinephrine binding / phospholipase C-activating adrenergic receptor signaling pathway / alpha-1B adrenergic receptor binding / negative regulation of norepinephrine secretion / negative regulation of insulin secretion involved in cellular response to glucose stimulus / negative regulation of epinephrine secretion / negative regulation of calcium ion-dependent exocytosis / heterotrimeric G-protein binding / response to alcohol / intestinal absorption / positive regulation of potassium ion transport / dopaminergic synapse / thioesterase binding / thermoception / Surfactant metabolism / adenylate cyclase-inhibiting adrenergic receptor signaling pathway / norepinephrine binding / positive regulation of membrane protein ectodomain proteolysis / Adrenoceptors / adrenergic receptor signaling pathway / positive regulation of wound healing / response to morphine / negative regulation of calcium ion transport / positive regulation of epidermal growth factor receptor signaling pathway / negative regulation of insulin secretion / Rho protein signal transduction / negative regulation of lipid catabolic process / regulation of vasoconstriction / cellular response to hormone stimulus / adenylate cyclase-activating adrenergic receptor signaling pathway / presynaptic active zone membrane / presynaptic modulation of chemical synaptic transmission / axon terminus / positive regulation of cytokine production / female pregnancy / platelet activation / vasodilation / GABA-ergic synapse / postsynaptic density membrane / epidermal growth factor receptor signaling pathway / adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway / actin cytoskeleton organization / glucose homeostasis / Adrenaline,noradrenaline inhibits insulin secretion / G alpha (z) signalling events / adenylate cyclase-activating G protein-coupled receptor signaling pathway / positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction / G alpha (i) signalling events / DNA replication / basolateral plasma membrane / Ras protein signal transduction / positive regulation of MAPK cascade / signaling receptor complex / positive regulation of cell migration / G protein-coupled receptor signaling pathway / neuronal cell body / positive regulation of cell population proliferation / protein kinase binding / glutamatergic synapse / protein homodimerization activity / plasma membrane / cytoplasm Similarity search - Function | |||||||||
| Biological species | Homo sapiens (human) | |||||||||
| Method | single particle reconstruction / cryo EM / Resolution: 2.8 Å | |||||||||
Authors | Srinivasan K / Xu X / Mailhot O / Manglik A / Shoichet B | |||||||||
| Funding support | United States, 1 items
| |||||||||
Citation | Journal: bioRxiv / Year: 2026 Title: Toward a Random Background for Ligand Optimization. Abstract: Ligand optimization is central to drug discovery as hundreds of analogs might be designed and synthesized between an initial hit and a therapeutic candidate. The efficiency of this process is ...Ligand optimization is central to drug discovery as hundreds of analogs might be designed and synthesized between an initial hit and a therapeutic candidate. The efficiency of this process is unclear, at least partly because there is no random background for optimization against which to compare. Such a random background might emerge from synthetically accessible but otherwise systematic random small substitutions across starting ligands, measuring likelihood of achieving a substantial improvement in affinity/potency or other property by any single perturbation. Recent literature and ligand-affinity/potency databases suggest that perhaps 10% of analogs with minor modifications improve upon a parent's potency substantially (by ≥10-fold), but this number is clouded by reporting bias, intentional improvement, and inter-group reproducibility. To begin to establish a background expectation for ligand optimization, we comprehensively and systematically modified 18 lead molecules across six targets with single atom changes; 257 compounds were synthesized. Unexpectedly, 11.2% of these random small perturbation analogs improved potency by ≥10-fold over their parents. Conversely, these more potent analogs typically had worse pharmacokinetics (e.g. reduced metabolic stability, lower plasma free fraction). While it was possible to find analogs where the potency increase compensated for inferior exposure and half-life, resulting in more potent compounds in vivo, overall a frustrated landscape for ligand optimization is revealed. This study begins to establish a background expectation for ligand potency optimization and offers a simple strategy to do so. It also begins to quantify the challenges confronting the field in moving beyond in vitro potency. | |||||||||
| History |
|
-
Structure visualization
| Supplemental images |
|---|
-
Downloads & links
-EMDB archive
| Map data | emd_71718.map.gz | 167.7 MB | EMDB map data format | |
|---|---|---|---|---|
| Header (meta data) | emd-71718-v30.xml emd-71718.xml | 37.2 KB 37.2 KB | Display Display | EMDB header |
| FSC (resolution estimation) | emd_71718_fsc.xml | 16.5 KB | Display | FSC data file |
| Images | emd_71718.png | 61 KB | ||
| Masks | emd_71718_msk_1.map | 178 MB | Mask map | |
| Filedesc metadata | emd-71718.cif.gz | 8.7 KB | ||
| Others | emd_71718_additional_1.map.gz emd_71718_half_map_1.map.gz emd_71718_half_map_2.map.gz | 88.5 MB 165.3 MB 165.3 MB | ||
| Archive directory | https://data.pdbj.org/pub/emdb/structures/EMD-71718 ftp://data.pdbj.org/pub/emdb/structures/EMD-71718 | HTTPS FTP |
-Related structure data
| Related structure data | ![]() 9plnMC ![]() 14abC ![]() 14amC ![]() 14anC ![]() 14aoC ![]() 14apC ![]() 7iiwC ![]() 7iixC ![]() 7iiyC ![]() 7iizC ![]() 7ij0C ![]() 7ij1C ![]() 7ij2C ![]() 7ij3C ![]() 7ij4C ![]() 7ij5C ![]() 7ij6C ![]() 7ij7C ![]() 7ij8C ![]() 7ij9C ![]() 7ijaC ![]() 7ijbC ![]() 7ijcC ![]() 7ijdC ![]() 7ijeC ![]() 7ijfC ![]() 7ijgC ![]() 7ijhC ![]() 7ijiC ![]() 7ijjC ![]() 7ijkC ![]() 7ijlC ![]() 7ijmC ![]() 9ploC M: atomic model generated by this map C: citing same article ( |
|---|---|
| Similar structure data | Similarity search - Function & homology F&H Search |
-
Links
| EMDB pages | EMDB (EBI/PDBe) / EMDataResource |
|---|---|
| Related items in Molecule of the Month |
-
Map
| File | Download / File: emd_71718.map.gz / Format: CCP4 / Size: 178 MB / Type: IMAGE STORED AS FLOATING POINT NUMBER (4 BYTES) | ||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Annotation | Local refinement sharpened map of Alpha2a adrenergic receptor in complex with compound 4905 | ||||||||||||||||||||||||||||||||||||
| Projections & slices | Image control
Images are generated by Spider. | ||||||||||||||||||||||||||||||||||||
| Voxel size | X=Y=Z: 0.8189 Å | ||||||||||||||||||||||||||||||||||||
| Density |
| ||||||||||||||||||||||||||||||||||||
| Symmetry | Space group: 1 | ||||||||||||||||||||||||||||||||||||
| Details | EMDB XML:
|
-Supplemental data
-Mask #1
| File | emd_71718_msk_1.map | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Projections & Slices |
| ||||||||||||
| Density Histograms |
-Additional map: Local refinement unsharpened map of Alpha2a adrenergic receptor...
| File | emd_71718_additional_1.map | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Annotation | Local refinement unsharpened map of Alpha2a adrenergic receptor in complex with compound 4905 | ||||||||||||
| Projections & Slices |
| ||||||||||||
| Density Histograms |
-Half map: Half Map A of Alpha2a adrenergic receptor in...
| File | emd_71718_half_map_1.map | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Annotation | Half Map A of Alpha2a adrenergic receptor in complex with compound 4905 | ||||||||||||
| Projections & Slices |
| ||||||||||||
| Density Histograms |
-Half map: Half Map B of Alpha2a adrenergic receptor in...
| File | emd_71718_half_map_2.map | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Annotation | Half Map B of Alpha2a adrenergic receptor in complex with compound 4905 | ||||||||||||
| Projections & Slices |
| ||||||||||||
| Density Histograms |
-
Sample components
-Entire : Alpha2a adrenergic receptor in complex with Go heterotrimer, scFv...
| Entire | Name: Alpha2a adrenergic receptor in complex with Go heterotrimer, scFv16, and compound 4905. |
|---|---|
| Components |
|
-Supramolecule #1: Alpha2a adrenergic receptor in complex with Go heterotrimer, scFv...
| Supramolecule | Name: Alpha2a adrenergic receptor in complex with Go heterotrimer, scFv16, and compound 4905. type: complex / ID: 1 / Parent: 0 / Macromolecule list: #1 |
|---|---|
| Source (natural) | Organism: Homo sapiens (human) |
-Macromolecule #1: Alpha-2A adrenergic receptor
| Macromolecule | Name: Alpha-2A adrenergic receptor / type: protein_or_peptide / ID: 1 / Number of copies: 1 / Enantiomer: LEVO |
|---|---|
| Source (natural) | Organism: Homo sapiens (human) |
| Molecular weight | Theoretical: 53.643855 KDa |
| Recombinant expression | Organism: ![]() |
| Sequence | String: MKTIIALSYI FCLVFADYKD DDDASIDFRQ EQPLAEGSFA PMGSLQPDAG NASWNGTEAP GGGARATPYS LQVTLTLVCL AGLLMLLTV FGNVLVIIAV FTSRALKAPQ NLFLVSLASA DILVATLVIP FSLANEVMGY WYFGKAWCEI YLALDVLFCT S SIVHLCAI ...String: MKTIIALSYI FCLVFADYKD DDDASIDFRQ EQPLAEGSFA PMGSLQPDAG NASWNGTEAP GGGARATPYS LQVTLTLVCL AGLLMLLTV FGNVLVIIAV FTSRALKAPQ NLFLVSLASA DILVATLVIP FSLANEVMGY WYFGKAWCEI YLALDVLFCT S SIVHLCAI SLDRYWSITQ AIEYNLKRTP RRIKAIIITV WVISAVISFP PLISIEKKGG GGGPQPAEPR CEINDQKWYV IS SCIGSFF APCLIMILVY VRIYQIAKRR TRVPPSRRGP DAVAAPPGGT ERRPNGLGPE RSAGPGGAEA EPLPTQLNGA PGE PAPAGP RDTDALDLEE SSSSDHAERP PGPRRPERGP RGKGKARASQ VKPGDSLPRR GPGATGIGTP AAGPGEERVG AAKA SRWRG RQNREKRFTF VLAVVIGVFV VCWFPFFFTY TLTAVGCSVP RTLFKFFFWF GYCNSSLNPV IYTIFNHDFR RAFKK ILCR GDRKRIV UniProtKB: Alpha-2A adrenergic receptor |
-Macromolecule #2: N-(5-methylnaphthalen-1-yl)pyridin-4-amine
| Macromolecule | Name: N-(5-methylnaphthalen-1-yl)pyridin-4-amine / type: ligand / ID: 2 / Number of copies: 1 / Formula: A1CIU |
|---|---|
| Molecular weight | Theoretical: 234.296 Da |
-Experimental details
-Structure determination
| Method | cryo EM |
|---|---|
Processing | single particle reconstruction |
| Aggregation state | particle |
-
Sample preparation
| Concentration | 2.6 mg/mL | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Buffer | pH: 7.5 Component:
Details: CHS was solubilized in LMNG and GDN prior to diluting into buffers. | |||||||||||||||||||||
| Grid | Model: UltrAuFoil R1.2/1.3 / Material: GOLD / Mesh: 300 / Support film - Material: GOLD / Support film - topology: HOLEY / Pretreatment - Type: GLOW DISCHARGE / Pretreatment - Time: 30 sec. / Pretreatment - Atmosphere: OTHER / Details: 15 mA current | |||||||||||||||||||||
| Vitrification | Cryogen name: ETHANE / Chamber humidity: 100 % / Chamber temperature: 277.15 K / Instrument: FEI VITROBOT MARK IV |
-
Electron microscopy
| Microscope | TFS KRIOS |
|---|---|
| Image recording | Film or detector model: GATAN K3 (6k x 4k) / Number grids imaged: 1 / Number real images: 10305 / Average exposure time: 2.0 sec. / Average electron dose: 0.596 e/Å2 |
| Electron beam | Acceleration voltage: 300 kV / Electron source: FIELD EMISSION GUN |
| Electron optics | Illumination mode: FLOOD BEAM / Imaging mode: BRIGHT FIELD / Nominal defocus max: 3.0 µm / Nominal defocus min: 1.5 µm / Nominal magnification: 105000 |
| Sample stage | Specimen holder model: FEI TITAN KRIOS AUTOGRID HOLDER / Cooling holder cryogen: NITROGEN |
| Experimental equipment | ![]() Model: Titan Krios / Image courtesy: FEI Company |
+
Image processing
-Atomic model buiding 1
| Initial model | PDB ID: Chain - Source name: PDB / Chain - Initial model type: experimental model |
|---|---|
| Refinement | Protocol: RIGID BODY FIT / Overall B value: 110.6 |
| Output model | ![]() PDB-9pln: |
Movie
Controller
About Yorodumi



Keywords
Homo sapiens (human)
Authors
United States, 1 items
Citation










































Z (Sec.)
Y (Row.)
X (Col.)





















































FIELD EMISSION GUN


